ライフサイエンスコーパス: methyl-CpG-binding protein 2

1 sed by mutations in the X-linked gene MECP2 (methyl-CpG-binding protein 2).

2 , hypoxia-related transcription factors, and methyl CpG binding protein 2.

3 d with mutations in MECP2, the gene encoding methyl CpG-binding protein 2.

4 of de novo DNA methyltransferase DNMT3a and methyl-CpG-binding protein 2.

5 order caused by mutations in MECP2, encoding methyl-CpG-binding protein 2.

6 from mutation in the mecp2 gene that encodes methyl CpG binding protein 2, a transcriptional represso

7 so notable are two neuron-enriched proteins, methyl CpG-binding protein 2 and polypyrimidine tract-bi

8 in repression of PPARgamma: increased MeCP2 (methyl CpG binding protein 2) and HP-1alpha co-repressor

9 RTT), caused by mutations in MECP2 (encoding methyl CpG binding protein 2), and Angelman syndrome (AS

10 tone methyltransferases and demethylases, or methyl CpG binding protein 2, and a significant decrease

11 he heterochromatin-associated proteins MBD1, methyl-CpG-binding protein 2, and HP1alpha.

12 Mutations in MECP2, encoding methyl-CpG-binding protein 2, are responsible for approx

13 in MECP2, encoding the epigenetic regulator methyl-CpG-binding protein 2, are the predominant cause

14 1 and 2, histone methyl-transferase G9a, and methyl CpG binding protein 2 at the promoters of target

15 Mutations of MECP2 (Methyl-CpG Binding Protein 2) cause Rett syndrome.

16 Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the m

17 5-hmC levels were inversely correlated with methyl-CpG-binding protein 2 dosage, a protein encoded b

18 nuclear antigen, heterochromatin protein 1, methyl-CpG binding protein 2, Enhancer of Zeste homolog

19 Methyl-CpG binding protein 2-expressing neurons were mor

20 T) arises from loss-of-function mutations in methyl-CpG binding protein 2 gene (Mecp2), but fundament

21 Mutations in the methyl-CpG binding protein 2 gene, Mecp2, affect primari

22 The aim of this study was to examine methyl-CpG-binding protein 2 gene (MECP2) polymorphisms

23 ace since the identification of mutations in methyl-CpG-binding protein 2 gene (MECP2) was first repo

24 sorder most often caused by mutations in the methyl-CpG-binding protein 2 gene (MECP2).

25 rodevelopmental disorder in which the MECP2 (methyl CpG-binding protein 2) gene is mutated.

26 n two such factors, CREB-binding protein and methyl-CpG-binding protein 2, have begun to reveal how e

27 se 1, ten-eleven-translocation hydroxylases, methyl CpG binding protein 2, histone deacetylases, and

28 decreased C/EBPbeta and pCREB and increased methyl-CpG binding protein-2, histone-deacetylase-2, and

29 MeCP2 (methyl CpG binding protein 2) is a key player in recogni

30 X-linked gene encoding the epigenetic factor methyl-CpG-binding protein-2, is mutated in Rett syndrom

31 X-linked gene encoding the epigenetic factor methyl-CpG-binding protein-2, is mutated in Rett syndrom

32 nction mutations of the X-linked gene MECP2 (methyl-CpG binding protein 2) lead to severe neurodevelo

33 nteraction between histone deacetylase 2 and methyl-CpG-binding protein 2, leading to suppressed hist

34 n immunoprecipitation analysis revealed that methyl-CpG-binding protein 2 (MBD2) is associated prefer

35 activity by 30%, and reduced the binding of methyl CpG binding protein 2 (MeCP2) and increased the b

36 Mutations in methyl CpG binding protein 2 (MeCP2) are mainly responsi

37 Mutations in the transcriptional repressor methyl CpG binding protein 2 (MeCP2) are responsible for

38 Mutations in the gene encoding methyl CpG binding protein 2 (MeCP2) are the primary cau

39 mal expression of the X-linked gene encoding methyl CpG binding protein 2 (MeCP2) cause a spectrum of

40 tification of mutations in the gene encoding methyl CpG binding protein 2 (MeCP2) in Rett syndrome re

41 mainly caused by mutations of a single gene methyl CpG binding protein 2 (MeCP2) on the X chromosome

42 der caused by mutations in the gene encoding methyl CpG binding protein 2 (MeCP2) that occur sporadic

43 chromatin immunoprecipitation (ChIP) assays, methyl CpG binding protein 2 (MeCP2) was shown to bind t

44 polypeptide backbone dynamics of full-length methyl CpG binding protein 2 (MeCP2) when free in soluti

45 (HP1), polycomb protein complex 1 (PRC1) and methyl CpG binding protein 2 (MeCP2), at the COX-2 promo

46 The X-linked transcriptional repressor methyl CpG binding protein 2 (MeCP2), known for its role

47 tone H1, high mobility group D1 (HMGD1), and methyl CpG binding protein 2 (MeCP2), on the biophysical

48 n the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).

49 We also demonstrate that methyl CpG binding protein-2 (MeCP2) levels affect TRPC6

50 r the expression of the epigenetic regulator methyl CpG-binding protein 2 (MeCP2) in key brain reward

51 Both increases and decreases in methyl CpG-binding protein 2 (MeCP2) levels cause neurod

52 l activity-induced phosphorylation (NAIP) of methyl CpG-binding protein 2 (MeCP2) precedes its releas

53 munoprecipitation analysis revealed that the methyl CpG-binding protein 2 (MeCP2) was enriched in the

54 eport that HMGN1 modulates the expression of methyl CpG-binding protein 2 (MeCP2), a DNA-binding prot

55 tion in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how di

56 structure and domain organization of native methyl CpG-binding protein 2 (MeCP2), the recombinant hu

57 is active epigenetic state was replaced by a methyl CpG-binding protein 2 (MeCP2)-containing repressi

58 n caused by mutations in the gene coding for methyl CpG-binding protein 2 (MECP2).

59 is caused by mutations in the gene encoding methyl CpG-binding protein 2 (MeCP2).

60 by mutations in a transcriptional regulator, methyl CpG-binding protein 2 (MECP2).

61 s caused by mutations in the gene coding for methyl CpG-binding protein 2 (MeCP2).

62 ostnatal disorder, results from mutations in Methyl CpG-binding protein 2 (MECP2).

63 ontrol of levels of the epigenetic regulator methyl CpG-binding protein 2 (MeCP2).

64 inked gene encoding the transcription factor methyl-CpG binding protein 2 (MECP2) are the most freque

65 gene encoding the transcriptional repressor methyl-CpG binding protein 2 (MeCP2) cause the neurodeve

66 ss of function of the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2) causes the progress

67 function and gain-of-function alterations in methyl-CpG binding protein 2 (MeCP2) expression, respect

68 orrelates with the dissociation of DNMT1 and methyl-CpG binding protein 2 (MeCP2) from the promoter,

69 in which most patients have mutations in the methyl-CpG binding protein 2 (MECP2) gene and suffer fro

70 Mutations in the methyl-CpG binding protein 2 (MECP2) gene cause Rett syn

71 sults from loss of function mutations in the methyl-CpG binding protein 2 (MECP2) gene.

72 al deficits associated with mutations in the methyl-CpG binding protein 2 (MECP2) gene.

73 der that is associated with mutations in the methyl-CpG binding protein 2 (MECP2) gene.

74 e we report that Htt directly interacts with methyl-CpG binding protein 2 (MeCP2) in mouse and cellul

75 transcription in vitro and are recognized by methyl-CpG binding protein 2 (MeCP2) in neurons in vivo.

76 Methyl-CpG binding protein 2 (MeCP2) is a chromatin regu

77 Methyl-CpG binding protein 2 (MeCP2) is a nuclear protei

78 The methyl-CpG binding protein 2 (MeCP2) is a widely express

79 Methyl-CpG binding protein 2 (MeCP2) is critical for pro

80 n intriguing finding about the gene encoding methyl-CpG binding protein 2 (MeCP2) is that the loss-of

81 Functional deficiency of the X-linked methyl-CPG binding protein 2 (MeCP2) leads to the neurod

82 Here, we focus on methyl-CpG binding protein 2 (MECP2) restoration for RTT

83 tation (ChIP) assays assessed the binding of methyl-CpG binding protein 2 (MeCP2) to PPARgamma and ch

84 nding proteins (MBDs) demonstrated that only methyl-CpG binding protein 2 (MeCP2) was associated with

85 with mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCp2), a transcriptional

86 is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MeCP2), a transcriptional

87 is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MECP2), an epigenetic regu

88 ssed TFPI-2 promoter was associated with the methyl-CpG binding protein 2 (MeCP2), and that gene reac

89 ene coding for the transcriptional regulator methyl-CpG binding protein 2 (MeCP2), but despite much e

90 is of an X-linked, Rett syndrome (RTT) gene, methyl-CpG binding protein 2 (MECP2), in both rhesus and

91 Mutations in the transcriptional repressor, methyl-CpG binding protein 2 (MeCP2), result in a neurod

92 Mutations in the X-linked gene, methyl-CpG binding protein 2 (Mecp2), underlie a wide ra

93 The responsible gene, encoding methyl-CpG binding protein 2 (MeCP2), was recently disco

94 d by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2).

95 ily caused by mutations in the gene encoding methyl-CpG binding protein 2 (MeCP2).

96 d by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2).

97 omain (MBD) of one member of the MBP family, methyl-CpG binding protein 2 (MeCP2).

98 is caused by mutations in the gene encoding methyl-CpG binding protein 2 (MeCP2).

99 t arises from mutations in the X-linked gene methyl-CpG binding protein 2 (MeCP2).

100 caused by mutations in the epigenetic factor methyl-CpG binding protein 2 (MECP2).

101 cts to address CLN3 dosage effects using the methyl-CpG-binding protein 2 (MeCP2) and beta-actin prom

102 cts to address CLN3 dosage effects using the methyl-CpG-binding protein 2 (MeCP2) and beta-actin prom

103 -function mutations in the gene encoding the methyl-CpG-binding protein 2 (MeCP2) and is characterize

104 identify the mechanism of regulation of the methyl-CpG-binding protein 2 (MeCP2) and its functional

105 tions in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of som

106 We identify methyl-CpG-binding protein 2 (MeCP2) as the major 5hmC-b

107 In contrast, there was decreased methyl-CpG-binding protein 2 (MeCP2) association with BD

108 Methyl-CpG-binding protein 2 (MeCP2) binds methylated DN

109 s-of-function mutations in the X-linked gene Methyl-CpG-binding protein 2 (MECP2) cause a devastating

110 Mutations in the methyl-CpG-binding protein 2 (MECP2) cause more than 95%

111 Mutations in methyl-CpG-binding protein 2 (MeCP2) cause Rett syndrome

112 Mutations in methyl-CpG-binding protein 2 (MeCP2) cause Rett syndrome

113 Mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2) cause Rett syndrome

114 and SRFS1-interacting protein 1 (DFS70) and methyl-CpG-binding protein 2 (MeCp2) could be documented

115 dissociation of the transcription repressor methyl-CpG-binding protein 2 (MeCP2) from the promoter,

116 ong with the fact that chimeric mice lacking methyl-CpG-binding protein 2 (MeCP2) function die during

117 of function of the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2) gene, is associated

118 isorder caused primarily by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, which encodes

119 ntal disorder, is caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene.

120 opmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene.

121 ological disorder caused by mutations in the methyl-CpG-binding protein 2 (MeCP2) gene.

122 ouse models of the transcriptional modulator Methyl-CpG-Binding Protein 2 (MeCP2) have advanced our u

123 Methyl-CpG-binding protein 2 (MeCP2) is a transcriptiona

124 Methyl-CpG-binding protein 2 (MeCP2) is a ubiquitously e

125 Using the methyl-CpG-binding protein 2 (Mecp2) knockout (KO) mouse

126 Mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2) lead to disrupted n

127 The broad range of deficits caused by methyl-CpG-binding protein 2 (MeCP2) overexpression pose

128 The methyl-CpG-binding protein 2 (MeCP2) protein is an epige

129 Here we show that methyl-CpG-binding protein 2 (MeCP2) regulates behaviora

130 Mutations in the methyl-CpG-binding protein 2 (MeCP2) result in Rett synd

131 The Rett-syndrome-associated methyl-CpG-binding protein 2 (MeCP2) selectively binds m

132 We identified the epigenetic factor methyl-CpG-binding protein 2 (MeCP2) to be a direct and

133 Mutations in methyl-CpG-binding protein 2 (MECP2) underlie most cases

134 Loss- and gain-of-function mutations in methyl-CpG-binding protein 2 (MECP2) underlie two distin

135 RTT is caused by mutations in methyl-CpG-binding protein 2 (MeCP2), a nuclear protein

136 n in rodents are increased in the absence of methyl-CpG-binding protein 2 (MeCP2), a protein involved

137 evelopmental disorder caused by mutations in methyl-CpG-binding protein 2 (MECP2), a transcriptional

138 which encodes the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2), cause Rett syndrom

139 Mutations in MECP2, encoding methyl-CpG-binding protein 2 (MeCP2), cause the neurodev

140 Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2), encoding a transcr

141 ipts previously shown to be repressed by the Methyl-CpG-binding protein 2 (MeCP2), including serum- a

142 Germline mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2), underlie most case

143 MECP2 encodes methyl-CpG-binding protein 2 (MeCP2), which represses ge

144 evelopmental disorder caused by mutations in methyl-CpG-binding protein 2 (MECP2), with known disturb

145 duct Fos in the brains of wild-type (Wt) and methyl-CpG-binding protein 2 (Mecp2)-null (Null) mice, a

146 loss of function of the transcription factor methyl-CpG-binding protein 2 (MeCP2).

147 in MECP2, encoding the epigenetic regulator methyl-CpG-binding protein 2 (MeCP2).

148 gene encoding the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2).

149 der caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MECP2).

150 e births and is often caused by mutations in Methyl-CpG-binding protein 2 (MECP2).

151 der caused by mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2).

152 gene encoding the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2).

153 h additional chromatin components, including methyl-CpG-binding protein 2 (MeCP2).

154 ures, results from mutations in the gene for methyl-CpG-binding protein 2 (MeCP2).

155 adic mutations in the transcriptional factor methyl-CpG-binding protein 2 (MeCP2).

156 e caused by aberrations in the gene encoding methyl-CpG-binding protein 2 (MECP2).

157 and use, is primarily caused by mutations in methyl-CpG-binding protein 2 (MECP2).

158 the absence of the transcriptional repressor methyl-CpG-binding protein 2 (MeCP2).

159 mplexes with transcriptional factors such as methyl-CpG-binding protein 2 (MeCP2).

160 s-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2).

161 order caused by mutations in MECP2, encoding methyl-CpG-binding protein 2 (MeCP2).

162 order caused by mutations in MECP2, encoding methyl-CpG-binding protein 2 (MeCP2).

163 d by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2).

164 r caused by mutations in MECP2, encoding the methyl-CpG-binding protein 2 (MeCP2).

165 d by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2).

166 evelopmental disorder caused by mutations in Methyl-CpG-binding protein 2 (MECP2).

167 evelopmental disorder caused by mutations in Methyl-CpG-binding protein 2 (MECP2).

168 on, respectively, of the same critical gene, methyl-CpG-binding protein 2 (MECP2).

169 order that is usually caused by mutations in Methyl-CpG-binding Protein 2 (MECP2).

170 gene encoding the transcriptional modulator methyl-CpG-binding protein 2 (MeCP2).

171 sors [histone deacetylases, mSin3A, Brm, and methyl-CpG-binding protein 2 (MeCP2)].

172 ological disorder, is caused by mutations in methyl-CpG-binding protein 2 (MECP2; OMIM 300005), a ubi

173 m, we revealed a genotype-specific effect of methyl-CpG-binding protein-2 (MeCP2) dysfunction on iPSC

174 caused by loss-of-function mutations in the Methyl-CpG-binding protein-2 (MECP2) gene and is charact

175 rity of cases, by a sporadic mutation in the Methyl-CpG-binding protein-2 (MeCP2) gene.

176 cent identification of mutations in the gene methyl-Cpg-binding protein-2 (MECP2) in girls with Rett

177 ool and downstream signaling in mice lacking methyl-CpG-binding protein-2 (Mecp2) is unknown.

178 Increased dosage of methyl-CpG-binding protein-2 (MeCP2) results in a dramat

179 d by duplications spanning the gene encoding methyl-CpG-binding protein-2 (MeCP2), a protein involved

180 P-3 promoter influenced the binding of Sp-1, methyl-CpG-binding protein-2 (MeCP2), and histone deacet

181 rder caused by loss-of-function mutations in methyl-CpG-binding protein-2 (MeCP2).

182 Mutations in MECP2 and Mecp2 (encoding methyl-CpG binding protein 2 [MeCP2]) cause distinct neu

183 , peripherin, plasma glutathione peroxidase, methyl CpG-binding protein 2, retinal S-antigen, ErbB2 p

184 MECP2 encodes methyl-CpG-binding protein 2 that acts as a transcriptio

185 e found a significant increase in binding of methyl-CpG binding protein 2 to the "cytosine-phosphate-

186 in remodelling by its interaction with MBD2 (methyl CpG-binding protein 2), underlying FAK regulation